Trial Profile

Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belzutifan (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms LITESPARK-013
Sponsors Merck Sharp & Dohme

Most Recent Events

11 Feb 2025 Planned End Date changed from 4 Oct 2025 to 4 Oct 2026.
24 Oct 2023 Results (cutoff data was February 10, 2023) assessing the safety and efficacy of two doses of belzutifan in patients with advanced RCC, presented at the 48th European Society for Medical Oncology Congress.
29 Nov 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com